Literature DB >> 21289234

How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis.

Gregory W van Wyk1, Philip L Hazell, Michael R Kohn, Renee E Granger, Richard J Walton.   

Abstract

OBJECTIVE: To assess how threshold oppositional defiant disorder (ODD), inattention, and hyperactivity-impulsivity affect the response to atomoxetine versus methylphenidate.
METHOD: Systematic review of randomized controlled trials (RCTs; ≥6 weeks follow-up). The primary measure was core symptom response-≥40% reduction in ADHD Rating Scale-IV-Parent Version: investigator administered and scored total or domain subscores, as appropriate.
RESULTS: Data from 1,391 children and adolescents (823 atomoxetine, 568 methylphenidate; 7 RCTs) were meta-analyzed. The mean difference in response rates for patients with ODD was 0.6% (95% confidence interval [CI] = -11.9%-13.1%). The "without ODD" patient group showed significant between-trial heterogeneity (p < .001). Response rate differences for patients meeting the threshold for inattention or hyperactivity-impulsivity were -3.1% (95% CI = -11.5%-5.3%) and -4.9% (95% CI = -14.3%-4.4%), respectively.
CONCLUSIONS: Meeting the threshold criteria for oppositionality, inattention, or hyperactivity-impulsivity did not alter core ADHD symptom response to atomoxetine versus methylphenidate, which was equivalent.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289234     DOI: 10.1177/1087054710389989

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  6 in total

Review 1.  The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.

Authors:  Nicola C Savill; Jan K Buitelaar; Ernie Anand; Kathleen Ann Day; Tamás Treuer; Himanshu P Upadhyaya; David Coghill
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

2.  Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Robert L Findling; Keith McBurnett; Carla White; Sharon Youcha
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-06       Impact factor: 2.576

Review 3.  A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities.

Authors:  David B Clemow; Chris Bushe; Michele Mancini; Michael H Ossipov; Himanshu Upadhyaya
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-03       Impact factor: 2.570

4.  Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys.

Authors:  Ana Cubillo; Anna B Smith; Nadia Barrett; Vincent Giampietro; Michael J Brammer; Andrew Simmons; Katya Rubia
Journal:  Cereb Cortex       Date:  2012-10-09       Impact factor: 5.357

5.  Noradrenergic versus dopaminergic modulation of impulsivity, attention and monitoring behaviour in rats performing the stop-signal task: possible relevance to ADHD.

Authors:  A Bari; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2013-05-17       Impact factor: 4.530

Review 6.  Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review.

Authors:  Noa Tsujii; Masahide Usami; Noriyuki Naya; Toshinaga Tsuji; Hirokazu Mishima; Junko Horie; Masakazu Fujiwara; Junzo Iida
Journal:  Neurol Ther       Date:  2021-06-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.